| scholarly article | Q13442814 |
| P50 | author | Maria Sibilia | Q41133496 |
| Alberto J Schuhmacher | Q42574187 | ||
| Carmen Guerra | Q42574190 | ||
| P2093 | author name string | Mariano Barbacid | |
| Carolina Navas | |||
| Isabel Hernández-Porras | |||
| P2860 | cites work | Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 |
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. | Q27851572 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 | ||
| Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma | Q29616287 | ||
| Pancreatic cancer | Q29616288 | ||
| Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Pancreatic cancer | Q29622871 | ||
| Pancreatic cancer. | Q30490247 | ||
| Molecular signatures of pancreatic cancer | Q33918801 | ||
| Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma | Q34379846 | ||
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
| Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma | Q34642090 | ||
| The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. | Q34681112 | ||
| Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. | Q34786695 | ||
| Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma | Q35825974 | ||
| Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer | Q36550798 | ||
| nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer | Q36901035 | ||
| PI3K and STAT3: a new alliance. | Q37986079 | ||
| The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma | Q38447221 | ||
| Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. | Q39310774 | ||
| STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. | Q39540918 | ||
| Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma | Q39885220 | ||
| EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma | Q40282973 | ||
| Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context | Q40637553 | ||
| Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia | Q41816001 | ||
| Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence | Q42573716 | ||
| Tumour biology: senescence in premalignant tumours | Q42802962 | ||
| Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma | Q44255802 | ||
| Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. | Q53329413 | ||
| Pancreatic Cancer | Q54135367 | ||
| EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer | Q57697054 | ||
| Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer | Q60594558 | ||
| Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice | Q61776577 | ||
| Ductal metaplasia of human exocrine pancreas and its association with carcinoma | Q70078799 | ||
| Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates | Q80378426 | ||
| P433 | issue | 3 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 318-330 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma | |
| P478 | volume | 22 |
| Q36140634 | A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells |
| Q36437111 | A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma |
| Q42216847 | A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes. |
| Q37744279 | A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer |
| Q38902585 | A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. |
| Q59339787 | A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases |
| Q53224745 | A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. |
| Q27324447 | ADAM8 as a drug target in pancreatic cancer. |
| Q61799832 | ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma |
| Q47661281 | ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. |
| Q38922230 | Acinar cell plasticity and development of pancreatic ductal adenocarcinoma |
| Q35136815 | Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies |
| Q37113394 | Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism |
| Q96136047 | An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development |
| Q37628092 | Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas |
| Q54118277 | Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. |
| Q36169365 | Anterior Gradient 2 (AGR2) Induced Epidermal Growth Factor Receptor (EGFR) Signaling Is Essential for Murine Pancreatitis-Associated Tissue Regeneration |
| Q89520977 | CA19-9 as a therapeutic target in pancreatitis |
| Q39140268 | Canonical wnt signaling is required for pancreatic carcinogenesis |
| Q90566625 | Carcinogenesis of Pancreatic Ductal Adenocarcinoma |
| Q38730160 | Cellular and molecular aspects of pancreatic cancer |
| Q36801167 | Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer |
| Q30410012 | Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer |
| Q35659511 | Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer |
| Q36299606 | Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade |
| Q35643021 | Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization |
| Q90671653 | Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models |
| Q38995143 | Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease |
| Q33910221 | Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis |
| Q47141971 | Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling |
| Q38321245 | Current adjuvant therapeutic approaches for pancreatic cancer |
| Q34371518 | DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer |
| Q37407226 | Diagnosis of pancreatic lesions collected by endoscopic ultrasound-guided fine-needle aspiration using next-generation sequencing |
| Q91595228 | Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q34246014 | Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma |
| Q36273532 | Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype |
| Q58550279 | EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling |
| Q92669175 | EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival |
| Q42109581 | EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression |
| Q37704531 | EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth |
| Q92528442 | EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells |
| Q47170368 | Effect of arenobufagin on human pancreatic carcinoma cells |
| Q38844551 | Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells |
| Q57021398 | Epigenetically Distinct Sister Chromatids and Asymmetric Generation of Tumor Initiating Cells |
| Q26781848 | GEMMs as preclinical models for testing pancreatic cancer therapies |
| Q38798496 | GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression |
| Q37641751 | Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling |
| Q41709484 | Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling. |
| Q37343012 | Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. |
| Q35657842 | Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer |
| Q53249482 | Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis. |
| Q88688533 | Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets |
| Q27002973 | Genetically engineered mouse models of pancreatic adenocarcinoma |
| Q26765438 | Genetics and biology of pancreatic ductal adenocarcinoma |
| Q89520937 | Glycosylation alterations in acute pancreatitis and pancreatic cancer: CA19-9 expression is involved in pathogenesis and maybe targeted by therapy |
| Q41966212 | Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. |
| Q92917425 | Hiding in plain sight |
| Q90465494 | ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer |
| Q41770555 | Identification and manipulation of biliary metaplasia in pancreatic tumors. |
| Q41856856 | Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma |
| Q55252335 | In vivo reprogramming drives Kras-induced cancer development. |
| Q40383441 | Inactivation of TGFβ receptor II signalling in pancreatic epithelial cells promotes acinar cell proliferation, acinar-to-ductal metaplasia and fibrosis during pancreatitis. |
| Q33727657 | Inflammation to cancer: The molecular biology in the pancreas (Review). |
| Q39008845 | Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. |
| Q37191934 | Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 |
| Q28504893 | Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance |
| Q33686279 | Intraductal tubulopapillary neoplasm accompanied by invasive carcinoma of the pancreas: A case report and review of the literature |
| Q36068611 | K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions |
| Q43083283 | KRAS above and beyond - EGFR in pancreatic cancer |
| Q33566777 | KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents |
| Q37673906 | KRas, ROS and the initiation of pancreatic cancer |
| Q34659332 | Kras as a key oncogene and therapeutic target in pancreatic cancer |
| Q40291371 | Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells |
| Q47754576 | Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. |
| Q27853310 | Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression |
| Q36546501 | Loss of p27Kip¹ promotes metaplasia in the pancreas via the regulation of Sox9 expression |
| Q47246517 | Luteolin inhibits pancreatitis‑induced acinar‑ductal metaplasia, proliferation and epithelial‑mesenchymal transition of acinar cells. |
| Q64100823 | MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC) |
| Q34283475 | Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors |
| Q36887721 | Mechanisms of resistance to EGFR targeted therapies |
| Q64108851 | Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib |
| Q99710192 | Metabolic regulation of EGFR effector and feedback signaling in pancreatic cancer cells requires K-Ras |
| Q37699563 | Mitochondrial and Oxidative Stress-Mediated Activation of Protein Kinase D1 and Its Importance in Pancreatic Cancer |
| Q35188581 | Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q37585776 | Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis |
| Q55364065 | Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells. |
| Q38370174 | Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer |
| Q26798453 | Molecular Targeted Intervention for Pancreatic Cancer |
| Q26751709 | Molecular therapeutics in pancreas cancer |
| Q34517052 | Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions |
| Q49788157 | Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. |
| Q92271692 | Myeloid Cell-Derived HB-EGF Drives Tissue Recovery After Pancreatitis |
| Q37600068 | Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer |
| Q35768232 | NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer |
| Q38916311 | NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas. |
| Q36367008 | NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation |
| Q89728673 | NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS |
| Q35651453 | New targeted therapies in pancreatic cancer |
| Q34657670 | Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. |
| Q51049205 | Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes. |
| Q34113460 | Oncogenic KRAS signalling in pancreatic cancer |
| Q42330768 | Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions |
| Q42324659 | Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling |
| Q93167473 | Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer |
| Q38238612 | One Hippo and many masters: differential regulation of the Hippo pathway in cancer |
| Q99548635 | Organotypic Culture of Acinar Cells for the Study of Pancreatic Cancer Initiation |
| Q34616196 | PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice |
| Q38537351 | PLCε signaling in cancer |
| Q55104265 | Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. |
| Q92959992 | Pancreatic Ductal Deletion of Hnf1b Disrupts Exocrine Homeostasis, Leads to Pancreatitis, and Facilitates Tumorigenesis |
| Q58759701 | Pancreatic Exocrine Tissue Architecture and Integrity are Maintained by E-cadherin During Postnatal Development |
| Q57423198 | Pancreatic cancer |
| Q38396634 | Pancreatic cancer: from state-of-the-art treatments to promising novel therapies |
| Q34590266 | Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α |
| Q37589374 | Pathogenesis of pancreatic cancer: lessons from animal models |
| Q26797248 | Perspectives in the treatment of pancreatic adenocarcinoma |
| Q37721562 | Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study |
| Q37059925 | Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice |
| Q38970683 | Polarization of the vacuolar adenosine triphosphatase delineates a transition to high-grade pancreatic intraepithelial neoplasm lesions |
| Q54963213 | Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q43877274 | Ras signaling is essential for skin development. |
| Q93013397 | RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer |
| Q36299502 | RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth |
| Q35071666 | Regeneration and repair of the exocrine pancreas |
| Q36037205 | Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1. |
| Q38815948 | Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. |
| Q38766765 | Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q38102106 | Roles for KRAS in pancreatic tumor development and progression |
| Q64095213 | SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer |
| Q53229089 | SOX9 regulates ERBB signalling in pancreatic cancer development. |
| Q64274365 | Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers |
| Q64890448 | Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. |
| Q47965403 | Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents |
| Q35188280 | Small-molecule modulation of Ras signaling |
| Q34410212 | Smarter drugs emerging in pancreatic cancer therapy |
| Q35687807 | Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages |
| Q30908891 | TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis |
| Q92641653 | TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis |
| Q48907560 | Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. |
| Q39007517 | Targeting reactive oxygen species in development and progression of pancreatic cancer |
| Q56929860 | The ERBB network facilitates KRAS-driven lung tumorigenesis |
| Q47817412 | The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation |
| Q27021883 | The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas |
| Q37271741 | The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer |
| Q26765230 | The Significance of Ras Activity in Pancreatic Cancer Initiation |
| Q93081350 | The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer |
| Q35954277 | The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma |
| Q38919135 | The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice |
| Q92917519 | The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice |
| Q38989132 | The impact of hypoxia in pancreatic cancer invasion and metastasis. |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q33827679 | The secret origins and surprising fates of pancreas tumors |
| Q35904248 | Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage |
| Q36296335 | Tissue-specific tumorigenesis: context matters |
| Q28307924 | Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis |
| Q38257126 | Translational research in oncology--10 years of progress and future prospects |
| Q87411406 | Tumorigenesis: Pushing pancreatic cancer to take off |
| Q43151916 | Unexpected insights for anti-EGFR cancer therapy |
| Q28083091 | Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models |
| Q33685931 | ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism |
| Q59336236 | miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2 |
| Q34375528 | microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions |
| Q97534390 | κB-Ras and Ral GTPases regulate acinar to ductal metaplasia during pancreatic adenocarcinoma development and pancreatitis |
Search more.